Author + information
- Liu Xing and
- Hong Yuan
Chronic kidney disease (CKD) is a key challenge for public health worldwide, and hypertension is one of the most prevalent cardiovascular risk factors for CKD. The majority of studies have been published as literature in the MEDLINE system to provide support for medical decisions. Due to the rapid increase in the amount of electronic information in the past decade, it is difficult for doctors to manually maintain current knowledge with the rapid growth of literature. The aim of our study is to recommend influential antihypertensive drugs for patients with CKD by mining the MEDLINE literature database using MedRank, a graph-based ranking algorithm. The ultimate goal is to support doctors to make more informed decision in prescribing antihypertensive drugs to CKD patients.
We used MedRank algorithm to calculate the most influential antihypertensive drugs for CKD based on MEDLINE literature database and compared the ranking differences with hypertension guidelines published by the Joint National Committee over time. A cross-sectional study of questionnaire survey was designed to compare the consistency between physicians' habits and the ranking results.
Over an exhaustive study on all research literatures published in MEDLINE, Irbesartan is ranked as the most influential antihypertensive drug for patients with CKD in our study. The status of loop diuretics has lessened over time, and the importance of angiotensin receptor blockers has increased rapidly. The recommended antihypertensive drug categories determined by MedRank appeared prior to the release of hypertension guidelines. The concordance between physician rankings collected via questionnaires and our system output rankings was not high (Average Overlap, 0.53±0.20); however, the concordance increased with increasing position of physicians (P<0.05). In contrast, no statistical difference in the concordance scores was found when factors such as area, age, gender, department, and hospital level were considered.
In conclusion, irbesartan was ranked as the most influential antihypertensive drug among CKD by MedRank. This approach is a potential method for medical literature discovery, decision support, and guideline development.